A separate 2027 target calls for adjusted diluted EPS growth of at least 12%, based on a 2026 adjusted earnings floor of at least $26.75 per share. Elevance also raised its 2026 adjusted diluted EPS floor to at least $29.
The updated 2026 adjusted EPS minimum, announced Oct. 21, is up from at least $27. Elevance also raised its floor for 2026 diluted earnings under generally accepted accounting principles (GAAP) to at least $22 from $20.10. The company attributed the guidance increase to continued operating momentum.
For 2027, Elevance’s growth target uses a 2026 adjusted earnings base of at least $26.75 per share. The calculation removes targeted one-time investments, other nonoperating items and nonrecurring net investment income. The release sets a growth rate but provides no standalone 2027 per-share forecast.
Elevance presents adjusted diluted EPS as supplementary information alongside its GAAP earnings.
In the third quarter, shareholders’ net income rose 14.8%, while medical membership fell and reportable segments operating gain declined 2%. The company’s third-quarter results and membership decline were reported earlier.
